Company intelligence / Profile preview

Unipure Biotech

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Unipure Biotech is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative gene and cell therapies. The company focuses on addressing unmet medical needs in rare diseases and chronic conditions, with a primary emphasis on hemophilia and metabolic disorders. Utilizing advanced Adeno-Associated Virus (AAV) vector technology and mRNA platforms, Unipure Biotech aims to provide long-term, curative treatments through a single administration. Their pipeline includes several candidates targeting Hemophilia A and B, which have progressed into clinical trials in China.

Therapeutic areas: HematologyRare DiseasesMetabolic Disorders
Modalities: Gene therapyCell therapymRNA-based drugs
Industry: Biotech

Beyond the preview

Go deeper on Unipure Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unipure Biotech.

Explore the full profile